Sameem Abedin, MD
Medical College of Wisconsin
7
7
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mehdi Hamadani, MD
Medical College of Wisconsin
Shared therapeutic areas:
Worked with same sponsors:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Mary M. Horowitz, MD, MS
Medical College of Wisconsin
Shared therapeutic areas:
Worked with same sponsors:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
All 7 trials loaded